Outcome analysis in patients with uterine sarcoma.
- Author:
Tosol YU
1
;
Hak Jae KIM
;
Hong Gyun WU
;
Sung Whan HA
;
Yong Sang SONG
;
Noh Hyun PARK
;
Jae Won KIM
Author Information
- Publication Type:Original Article
- Keywords: Uterus; Sarcoma; Neoplasms by histology type; Pelvic failure; Adjuvant radiotherapy
- MeSH: Carcinosarcoma; Follow-Up Studies; Humans; Multivariate Analysis; Pelvis; Radiotherapy; Radiotherapy, Adjuvant; Recurrence; Retrospective Studies; Sarcoma*; Sarcoma, Endometrial Stromal; Uterus
- From:Radiation Oncology Journal 2015;33(1):29-35
- CountryRepublic of Korea
- Language:English
- Abstract: PURPOSE: To analyze the prognostic factors for survivals and to evaluate the impact of postoperative whole pelvic radiotherapy (WPRT) on pelvic failure in patients with uterine sarcoma treated with radical surgery. MATERIALS AND METHODS: We retrospectively analyzed 75 patients with uterine sarcoma who underwent radical surgery with (n = 22) or without (n = 53) radiotherapy between 1990 and 2010. There were 23 and 52 patients with carcinosarcoma and non-carcinosarcoma (leiomyosarcoma, 22; endometrial stromal sarcoma, 25; others, 5), respectively. The median follow-up period was 64 months (range, 17 to 269 months). RESULTS: The 5-year overall survival (OS) and pelvic failure-free survival (PFFS) of total patients was 64.2% and 83.4%, respectively. Multivariate analysis revealed that mitotic count (p = 0.006) was a significant predictor of OS. However, factors were not found to be associated with PFFS. On analyzing each of the histologic subtypes separately, postoperative WPRT significantly reduced pelvic failure in patients with carcinosarcoma (10.0% vs. 53.7%; p = 0.046), but not in patients with non-carcinosarcoma (12.5% vs. 9.9%; p = 0.866). Among the patients with carcinosarcoma, 4 patients (17%) had recurrence within the pelvis and 3 patients (13%) had recurrence in other sites as an initial failure, whereas among the patients with non-carcinosarcoma, 3 patients (6%) experienced pelvic failure and 13 patients (25%) experienced distant failure. CONCLUSION: The most significant predictor of OS was mitotic count. Based on the improved PFFS after postoperative WPRT only in patients with carcinosarcoma and the difference in patterns of failure between histologic subtypes, optimal adjuvant treatment options should be offered to patients based on the risk of recurrence patterns.
